GlassScriptPhysician profile
Jessica Maher
NPI 1568071454
$5,355.14
in general payments reported to CMS, 2019-2025
25 companies · $1,673 in 2025
The $1,673 reported for 2025 was more than what 96% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $47.34 · 2021: $744 · 2022: $768 · 2023: $1,055 · 2024: $1,068 · 2025: $1,673.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,791 · Education: $4.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,791.02 |
| Education | $4.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $704.21 | 2021-2025 | Cequa |
| Bausch & Lomb Americas INC. | $698.57 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $555.31 | 2021-2025 | Rocklatan, Tryptyr, Clareon |
| Abbvie INC. | $462.68 | 2022-2025 | |
| Oyster Point Pharma, INC. | $451.55 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Dompe US, INC. | $376.53 | 2021-2025 | Oxervate |
| Biotissue Holdings INC. | $367.76 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $295.80 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $277.42 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $241.41 | 2021-2023 | |
| Mallinckrodt Hospital Products INC. | $168.63 | 2021-2025 | Acthar |
| Allergan, INC. | $142.06 | 2021 | |
| Coopervision INC. | $141.87 | 2023-2024 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Rayner Intraocular Lenses Limited | $98.99 | 2024-2025 | Omidria, Rayone Spheric, Rayone Emv |
| Harrow Eye, LLC | $70.80 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $55.23 | 2020-2021 | |
| Ani Pharmaceuticals, INC. | $44.37 | 2023-2024 | Purified Cortrophin Gel |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $34.47 | 2020-2021 | |
| Glaukos Corporation | $29.64 | 2024 | Photrexa |
| Astellas Pharma US INC | $29.36 | 2025 | Izervay |
| Johnson & Johnson Surgical Vision, INC. | $27.76 | 2022 | |
| Thea Pharma INC. | $25.12 | 2025 | Iyuzeh |
| Amgen INC. | $22.14 | 2025 | Tepezza |
| Eyevance Pharmaceuticals LLC | $18.17 | 2020 | |
| Johnson & Johnson Vision Care, INC. | $15.29 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Maher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.